fda warning letters compounded semaglutide tirzepatide september 2025 The U.S. health regulator asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. https://cnn.it/49uSrKw FDA to Restrict Ingredients Used

Key Findings 93.4% of patients would get bariatric surgery again 51.4% of patients would consider using GLP-1 drugs again 57.1% of GLP-1 patients reported losing at least 20 pounds 98.1% of bariatric surgery patients reported losing at least 20 pounds Median weight loss for bariatric surgery patients was 100 pounds, as opposed to 20 for GLP-1s Average weight loss for bariatric surgery was reported to be 101.2, as opposed to 24.9 for GLP-1 users 93.4% of Patients Would Get Bariatric Surgery Again Out of all patients surveyed, 93.4% said they would get bariatric surgery again

In a market now anchored by tirzepatide and the anticipation of even more potent next-generation agents, the same data is being assessed against a higher standard

Consult with a healthcare provider before starting any weight loss program

WeightWatchers helps members navigate insurance and understand their options, which can make a big difference in affordability

Current Psychiatry Reports, 26(2), 43-55